期刊
ANNUAL REVIEW OF ANALYTICAL CHEMISTRY
卷 2, 期 -, 页码 265-277出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev.anchem.1.031207.112942
关键词
biological variability; analytical variability; longitudinal sampling
资金
- National Institutes of Health National Cancer Institute [K25CA128666, R33CA105295]
- W.M. Keck Foundation
- NATIONAL CANCER INSTITUTE [R33CA105295, K25CA128666] Funding Source: NIH RePORTER
Biomarker discovery and proteomics have become synonymous with mass spectrometry in recent years. Although this conflation is an injustice to the many essential biomolecular techniques widely used in biomarker-discovery platforms, it underscores the power and potential of contemporary mass spectrometry. Numerous novel and powerful technologies have been developed around mass spectrometry, proteomics, and biomarker discovery over the past 20 years to globally study complex proteomes (e.g., plasma). However, very few large-scale longitudinal Studies have been carried out using these platforms to establish the analytical variability relative to true biological variability. The purpose of this review is not to cover exhaustively the applications of mass spectrometry to biomarker discovery, but rather to discuss the analytical methods and strategies that have been developed for mass spectrometry-based biomarker-discovery platforms and to place them in the context of the many challenges and opportunities yet to be addressed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据